Tag: Pharmaceuticals

Impact of GLP-1 Drugs on Health Insurance Premiums

Explore how GLP-1 drugs are impacting health insurance premiums and coverage, driving costs up for insurers and patients alike. Learn about regulatory changes.

Kansas Legislative Changes Impacting Health Insurance and Regulations

Explore Kansas' legislative changes affecting health insurance, including opioid immunity and naturopathic practice expansion. Stay informed for better compliance.

2024 Trends in Life Sciences M&A: Strategic Investments and Challenges

Explore the 2024 trends in life sciences mergers and acquisitions, focusing on strategic shifts, challenges, and insights for future investments.

Rising Healthcare Costs: Insights from Health Insurance Executives

Explore insights from health insurance executives on rising healthcare costs, premiums, and legislative responses. Understand the industry's complex dynamics today.

Insilico Medicine's Major Listing Boosts AI Innovation in Drug Discovery

Discover how Insilico Medicine's IPO on the Hong Kong Exchange is revolutionizing drug discovery with AI, drawing significant investor interest and market confidence.

Key Changes in Healthcare Insurance Landscape for 2025

Explore major changes in healthcare insurance for 2025, including drug pricing, Medicaid adjustments, and the role of AI in transforming risk management.

2025 Year-End U.S. Healthcare and Insurance Regulatory Update

Key regulatory and legislative developments shaping U.S. healthcare and insurance in late 2025, including APTC expirations, CMS innovations, FDA initiatives, and congressional healthcare policy efforts.

High-Cost Gene Therapies Challenge U.S. Insurance and Employer Coverage

Explore how high-cost gene therapies like Zolgensma are affecting U.S. employer-sponsored insurance and healthcare coverage amid rising costs and manufacturing challenges.

Federal Government Allocates $16B to Medicare Drug Plans Amid Rising Costs

The U.S. federal government has paid $16 billion to Medicare Part D insurers due to rising prescription drug spending, highlighting cost and risk management challenges in Medicare drug plans.

Eli Lilly's Mounjaro Added to China's National Health Insurance Program

Eli Lilly's diabetes drug Mounjaro is set to be included in China's national health insurance reimbursement list, boosting accessibility but with potential revenue impact from pricing adjustments.